Resverlogix advances RVX-208 IND program to parallel human microdosing

---

Resverlogix Corp. announces favourable results from previously announced toxicology studies, enabling Resverlogix to advance development timing on its RVX-208 Investigational New Drug (IND) program. The official IND enabling studies are now being initiated and the IND is targeted for submission during the third quarter of 2007.

With the advancement of this critical component of the drug development program for RVX-208, the focus will shift toward completion of an Investigational New Drug (IND) application to enable and support the clinical development program. Despite the advancement of this critical component, Resverlogix will continue the previously announced human microdosing program. The microdosing program will take place parallel to the IND program.

Resverlogix Corp. is focused on conducting research, development and commercialization of novel therapeutics that address the main underlying cause of cardiovascular disease (CVD). The company's secondary focus is TGF-Beta Shield (TM), a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis.